Thoratec Director Neil F. Dimick Sells 4,158 Shares (THOR)
Thoratec (NASDAQ:THOR) Director Neil F. Dimick sold 4,158 shares of the stock on the open market in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $32.15, for a total transaction of $133,679.70. Following the completion of the sale, the director now directly owns 40,953 shares in the company, valued at approximately $1,316,639. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Thoratec (NASDAQ:THOR) traded up 0.99% on Tuesday, hitting $32.57. 308,044 shares of the company’s stock traded hands. Thoratec has a one year low of $29.91 and a one year high of $43.58. The stock has a 50-day moving average of $32.64 and a 200-day moving average of $35.84. The company has a market cap of $1.850 billion and a price-to-earnings ratio of 25.39.
Thoratec (NASDAQ:THOR) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02. The company had revenue of $125.70 million for the quarter, compared to the consensus estimate of $122.56 million. During the same quarter in the previous year, the company posted $0.41 earnings per share. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, analysts predict that Thoratec will post $1.77 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at TheStreet downgraded shares of Thoratec from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Thoratec in a research note on Wednesday, May 21st. They now have a $33.00 price target on the stock. Finally, analysts at Citigroup Inc. reiterated an “overweight” rating on shares of Thoratec in a research note on Wednesday, May 7th. They now have a $43.00 price target on the stock, down previously from $45.00. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Thoratec has a consensus rating of “Buy” and an average price target of $42.67.
Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.